Anonymous ID: ffcbc6 May 15, 2020, 6:21 p.m. No.9193848   🗄️.is đź”—kun   >>4181 >>4300

>>9193647

 

Board of Directors

 

lotsa swampiness here with the connections to Stanford, Yale, MIT, Harvard, Wharton, CAl-Berkley, education-wise.

The "money" guy worked at UBS, Lehman Bros and founded Oaktree Capital

 

Henry Ji, Ph.D., Chairman

Henry Ji, Ph.D. co-founded and has served as a director of Sorrento since January 2006, and as its Chief Executive Officer and President since September 2012. Dr. Ji served as Sorrento’s Chief Scientific Officer from November 2008 to September 2012, and as its Interim Chief Executive Officer from April 2011 to September 2012.

 

Dorman Followwill

Dorman Followwill, age 54, has been Senior Partner, Transformational Health at Frost & Sullivan, a business consulting firm involved in market research and analysis, growth strategy consulting and corporate training across multiple industries, since 2016. Prior to that time, he served in various roles at Frost & Sullivan, including Partner on the Executive Committee managing the P&L of the business in Europe, Israel and Africa, and Partner overseeing the Healthcare and Life Sciences business in North America, since initially joining Frost & Sullivan to help found the Consulting practice in January 1988.

 

Kim D. Janda, Ph.D.

 

Dr. Janda has served as a director since April 2012. Dr. Janda has been the Ely R. Callaway, Jr. Chaired Professor in the Departments of Chemistry, Immunology and Microbial Science at The Scripps Research Institute (“TSRI”) since 1996 and as the Director of the Worm Institute of Research and Medicine (“WIRM”) at TSRI since 2005. Furthermore, Dr. Janda has served as a Skaggs Scholar within the Skaggs Institute of Chemical Biology, also at TSRI, since 1996.

 

Edgar Lee

Mr. Lee founded and was the portfolio manager of Oaktree Capital Management’s $5.5bn Strategic Credit strategy. He was also the CEO and Chief Investment Officer of Oaktree’s three business development companies (BDCs) including Oaktree Specialty Lending and Oaktree Strategic Income Corporations. Previously, he was an investment professional within the firm’s Opportunities Funds group and led the group’s investments in the media, technology and telecom industries. Prior to joining Oaktree in 2007, Mr. Lee worked within the Investment Banking division at UBS Investment Bank in Los Angeles, where he was responsible for advising clients on a number of equity and debt financings, buy-side and sell-side M&A, and recapitalizations. Before that, Mr. Lee was employed within the Fixed Income division at Lehman Brothers Inc. Prior experience includes work at Katzenbach Partners LLP and the Urban Institute. He received a B.A. degree in economics from Swarthmore College and his master’s degree from Harvard University. Mr. Lee serves as a director of Neo Performance Materials and previously served on the boards of Nine Entertainment and Charter Communications.

 

David Lemus

David Lemus, age 54, currently serves as a non-executive board member of BioHealth Innovation, Inc., The MIT Club of Washington DC and Proteros BioScience GmbH. From January 2016 to May 2017, he served as Interim Chief Financial Officer and Chief Operating Officer of Medigene AG, a publicly-listed German biotechnology company focused on the research and development of T-Cell-Receptor based immunotherapies.

 

moar here

https://sorrentotherapeutics.com/company/board-of-directors/